Document:

EX-10.10

 Exhibit 10.10 

 
 

 
 June 10, 2020 
 Agnes Rey-Giraud 
 RE: Board Service Continuation Letter Agreement 

Dear Agnes: 
 As you know, your
term as a director on the board of directors (the “Board”) of GoodRx Holdings, Inc., a Delaware corporation (“GoodRx”) will expire in August. GoodRx is delighted to invite you to continue serving in such position and will
recommend to the Board and the company’s stockholders to elect you for another term commencing on August 11, 2020. 
 This letter
summarizes your service and compensation as an outside Board member for such new term. To that effect, you acknowledge that you were paid in full any amounts due to you for your current service on the Board and that you were issued all equity
promised to you related thereof. For the avoidance of doubt, this letter does not affect your service as a manager on the board of managers of GoodRx Intermediate Holdings, LLC (“Intermediate”), a
wholly-owned subsidiary of GoodRx, which service has been continuous since appointment thereon. You acknowledge and agree that you will not be entitled to any further compensation for serving on the Board of
GoodRx or board of managers of Intermediate beyond what is described herein. 
 While independent directors ultimately serve at the pleasure
of stockholders, we would anticipate your service having a one-year term before coming due for re-election. 

Your compensation as a director includes cash compensation and an equity grant. The specifics associated with each compensation component are
as follows: 
 Cash compensation 

As a Board member, you will receive $30,000 in annual compensation which is to be paid quarterly and
pro-rated as necessary for a partial quarter of service. Further, you will be reimbursed for usual and customary travel expenses associated with your Board activity in a manner consistent with GoodRx’s
policies. 
 Equity grant 

It will be recommended to the Board that you be issued a non-statutory option to purchase 30,000 shares
of Common Stock of GoodRx under the Fourth Amended and Restated 2015 Equity Incentive Plan of GoodRx Holdings, Inc. (the “Option Plan”). The amount of shares will be determined in the sole discretion of the Board. Your option shares
will vest 

 
over time as you provide services to GoodRx. The vesting schedule shall be over a one-year period, with the shares vesting at the rate of 1/12th of the
total shares per month over twelve months from August 11, 2020, subject to your continuous provision of services to GoodRx. The exercise price of the option shares will be at least the fair market value of the Common Stock of GoodRx per share
on the date of grant by the Board. The option will be evidenced by the standard Stock Option Agreement of GoodRx and will be subject to the terms and conditions of the Option Plan. 

As a kind reminder, the Proprietary Information and Invention Assignment Agreement and the Indemnification Agreement you previously signed
will continue to govern your service as a director on the Board under the new term. 
 We look forward to continuing working with you to
make GoodRx a commercial and financial success. 
  

	
	Sincerely,
	
	 /s/ Trevor Bezdek

	Trevor Bezdek
	Co-Chief Executive Officer
	
	Agreed & Accepted:

			
		
	By:	 	 /s/ Agnes Rey-Giraud

	Name:	 	Agnes Rey-Giraud
	Date:	 	6/10/2020EX-10.11

 Exhibit 10.11 

 
 

 
 June 9, 2020 
 Jackie
Kosecoff 
 RE: Board Service (New Term) Letter Agreement 

Dear Jackie: 
 As you know, your
term as a director on the board of directors (the “Board”) of GoodRx Holdings, Inc., a Delaware corporation (“GoodRx”) recently expired. GoodRx is delighted to invite you to continue serving in such position, and is hereby
offering you a seat on its Board for another term, effective upon formal appointment by the Board and its stockholders. 
 This letter
summarizes your service and compensation as an outside Board member for such new term. To that effect, you acknowledge that you were paid in full any amounts due to you for your prior service on the Board and that you were issued all equity promised
to you related thereof. For the avoidance of doubt, this letter does not affect your service as a manager on the board of managers of GoodRx Intermediate Holdings, LLC (“Intermediate”), a
wholly-owned subsidiary of GoodRx, which service has been continuous since appointment thereto. You acknowledge and agree that you will not be entitled to any further compensation for serving on the Board of
GoodRx or board of managers of Intermediate beyond what is described herein. 
 Your compensation shall be as set forth below: 

Cash compensation 

As a Board member, you will receive $30,000 in annual compensation which is to be paid quarterly and
pro-rated as necessary for a partial quarter of service. Should you serve on the Audit Committee of the Board, you will receive an additional $8,000 in annual compensation, paid on the same schedule as set
forth in the prior sentence. Further, you will be reimbursed for usual and customary travel expenses associated with your Board activity in a manner consistent with GoodRx’s policies. 

Equity grant 
 It
will be recommended to the Board that you be issued a non-statutory option to purchase 30,000 shares of Common Stock of GoodRx under the Fourth Amended and Restated 2015 Equity Incentive Plan of GoodRx
Holdings, Inc. (the “Option Plan”). The amount of shares will be determined in the sole discretion of the Board. Your option shares will vest over time as you provide services to GoodRx. The vesting schedule shall be over a one-year period, with the shares vesting at the rate of 1/12th of the total shares per month over twelve 

 
months from your election date, subject to your continuous provision of services to GoodRx. The exercise price of the option shares will be at least the fair market value of the Common Stock of
GoodRx per share on the date of grant by the Board. The option will be evidenced by the standard Stock Option Agreement of GoodRx and will be subject to the terms and conditions of the Option Plan. 

In addition, you will be eligible to receive annual equity grants for continued Board service as approved by the Board or a committee thereof.

 We also request that you sign our standard form of Proprietary Information and Invention Assignment Agreement (the “Assignment
Agreement”), a copy of which is included with this letter for your review. 
 In your capacity as a director of GoodRx, you will be
indemnified to the fullest extent permitted by applicable law. The indemnification agreement you previously signed will continue to govern your service as a director on the Board under the new term. 

We look forward to continuing working with you to make GoodRx a commercial and financial success. 

 

	
	Sincerely,
	
	 /s/ Trevor Bezdek

	Trevor Bezdek
	Co-Chief Executive Officer
	
	Agreed & Accepted:

			
	By:	 	 /s/ Jacqueline Kosecoff

	Name:	 	Jacqueline Kosecoff
	Date:	 	6/10/2020EX-10.12

 Exhibit 10.12 

 
 

 
 August 20, 2020 
 Julie M. B.
Bradley 
 RE: Board Service Letter Agreement 

Dear Julie: 
 GoodRx is
delighted to invite you to join the board of directors of GoodRx Holdings, Inc. (the “Board”), as a director and as Audit Committee Chair and will recommend to the Board and the company’s stockholders to elect you to that role as of
August __, 2020. 
  
 This letter summarizes your service and
compensation as an outside Board member for such term. 
 Your compensation as a director includes cash compensation and an equity grant.
The specifics associated with each compensation component are as follows: 
 Cash compensation 

As a Board member, the Company agrees to provide you with $30,000 in annual compensation which is to be paid quarterly and pro-rated as
necessary for a partial quarter of service. Further, you will be reimbursed for usual and customary travel expenses associated with your Board activity in a manner consistent with GoodRx’s policies. 

In addition, as Audit Committee Chair, the Company agrees to pay you an incremental 

$20,000 in annual compensation, paid in the same manner as the compensation described above. 

Your compensation as a director remains subject to modification from time to time by the Board. 

Equity grant 
 The
Board expects to issue to you an award of 15,000 restricted stock units in relation to Common Stock of GoodRx under the Fourth Amended and Restated 2015 Equity Incentive Plan of GoodRx Holdings, Inc. (the “Plan”). The amount of restricted
stock units will be determined in the sole discretion of the Board. Your restricted stock units will vest over time as you provide services to GoodRx. The vesting schedule shall be over a three-year period, with the shares vesting at the rate of
1/36th of the total shares per month over thirty-six months from August 1, 2020, subject to your continuous provision of services to GoodRx. In addition, the Board expects to issue to you an award of 7,500 restricted stock units in relation to
Common Stock of GoodRx with a vesting schedule that shall be over a one-year period, with the shares vesting at the rate of 1/12th of the total shares per month over twelve months from August 1, 2020, subject to your continuous provision of
services to GoodRx. 

 We also request that you sign our standard form of Proprietary Information and Invention Assignment
Agreement (the “Assignment Agreement”), a copy of which is included with this letter for your review. 
 In your capacity as a director of GoodRx,
you will be indemnified to the fullest extent permitted by applicable law. We request that you sign the indemnification agreement which is included with this letter for your review. 

We look forward to continuing working with you to make GoodRx a commercial and financial success. 

 

			
	Sincerely,
	
	 /s/ Trevor Bezdek

	 Trevor Bezdek
 Co-Chief Executive
Officer

	
	Agreed & Accepted:
		
	By:	 	 /s/ Julie M.B. Bradley

	 Name: Julie M.B. Bradley
 Date:
  08 / 20 / 2020

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]